Pharma BD Deal Intelligence
A $7.1B (up to $7.25B) acquisition that gave Roche global rights to RVT-3101/afimkibart, a Phase 3-ready anti-TL1A antibody backed by strong Phase 2b ulcerative colitis data (36% clinical remission at week 56). Roche moved it swiftly into pivotal Phase III (Ametrine-2), positioning for a first regulatory filing around 2027—though Pfizer's retained rights outside the US/Japan cap Roche's global upside.
Roche acquired Telavant Holdings for $7.1B for gastrointestinal disease drug.
Roche agreed to acquire Telavant Holdings for $7.1 billion upfront and a $150 million near-term milestone payment, gaining rights to RVT-3101 for inflammatory…
Phase III induction study of afimkibart (RO7790121 / RVT-3101) in moderately-to-severely active ulcerative colitis; sponsor Hoffmann-La Roche; start Dec…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Roche acquired Telavant Holdings from Roivant Sciences in a deal announced October 23, 2023 and completed December 14, 2023, paying $7.1 billion upfront plus a $150 million near-term milestone (up to $7.25 billion). The transaction gave Roche US and Japanese development, manufacturing and commercialization rights to RVT-3101, a novel anti-TL1A (TNFSF15) IgG1 monoclonal antibody for inflammatory bowel disease; Pfizer retained rights outside those territories and Roche also took an option on a next-generation p40/TL1A bispecific. The asset was Phase 3-ready on Phase 2b TUSCANY-2 data showing 36% clinical remission and 50% endoscopic improvement at week 56 in ulcerative colitis. Under Roche the antibody was renamed afimkibart (RG6631 / RO7790121) and advanced to Phase III in ulcerative colitis (Ametrine-2, NCT06588855, initiated December 2024) and Phase II in Crohn's disease and atopic dermatitis, with Roche guiding to a first regulatory filing in UC around 2027.
Ulcerative colitis (UC) is a mature biologic market with aggressive oral and novel-mechanism entrants, threatening RVT-3101's commercial positioning. Anti-TNF biologics: infliximab (Remicade, J&J) and biosimilars, adalimumab (Humira, AbbVie) and biosimilars (~$14.4B 2023 global for Humira), and golimumab (Simponi, J&J). Anti-integrin: vedolizumab (Entyvio, Takeda, ~$5.6B FY2023). Anti-IL-12/23 and anti-IL-23p19: ustekinumab (Stelara, J&J), mirikizumab (Omvoh, Lilly; FDA-approved October 2023), risankizumab (Skyrizi, AbbVie; UC-approved 2024), and guselkumab (Tremfya, J&J; UC-approved 2024). Oral JAK inhibitors: tofacitinib (Xeljanz, Pfizer) and upadacitinib (Rinvoq, AbbVie; UC-approved March 2022). S1P receptor modulators: ozanimod (Zeposia, BMS) and etrasimod (Velsipity, Pfizer; approved October 2023). Direct TL1A class: tulisokibart (MK-7240, Merck) demonstrated positive Phase 2 ARTEMIS-UC data (NEJM 2024). For Roche, RVT-3101 enters a market defined by ~6 mechanistic classes and a direct Merck rival with an earlier regulatory path. Commercial lead framing: pricing power will be constrained by biosimilar TNFs and oral JAKs; the commercial thesis depends on TL1A biomarker stratification and superior long-term remission vs. IL-23 class.
Crohn's disease is a crowded immunology market where RVT-3101 (anti-TL1A) must differentiate against established MOAs. Anti-TNF biologics remain foundational: infliximab (Remicade, J&J, ~$1.8B 2023 including biosimilars), adalimumab (Humira, AbbVie, ~$14.4B 2023 global) and biosimilars (Amjevita, Hyrimoz, Yuflyma), and certolizumab pegol (Cimzia, UCB). Anti-IL-12/23 and anti-IL-23: ustekinumab (Stelara, J&J, ~$10.9B 2023 across indications) and risankizumab (Skyrizi, AbbVie; approved for CD June 2022). Anti-integrin: vedolizumab (Entyvio, Takeda, ~$5.6B FY2023). Oral JAK inhibitors: upadacitinib (Rinvoq, AbbVie; approved for CD May 2023). Novel MOAs in Phase 3 include etrasimod (Velsipity, Pfizer, S1P modulator; UC-approved, CD in development), mirikizumab (Omvoh, Lilly; UC-approved) and the direct TL1A class competitors tulisokibart (MK-7240/PRA023, Merck; Phase 3 ATLAS-CD) and afimkibart. For Roche, RVT-3101's commercial threat is intense: it enters behind Humira, Stelara, Skyrizi, Rinvoq, and Entyvio franchises with billions in entrenched revenue, and Merck's tulisokibart is a direct-class rival with a similar Phase 3 timeline. Differentiation likely requires biomarker-selected subpopulations.
Roche announced $7.1B Telavant deal to compete with Merck in the hot TL1A target space for IBD.
Roche acquired Telavant from Roivant for $7.1B upfront plus $150M milestone to gain RVT-3101 TL1A antibody for IBD.
RVT-3101 showed 36% clinical remission and 50% endoscopic improvement at week 56 in UC maintenance study.
Under Roche, RVT-3101 was renamed afimkibart (RG6631 / RO7790121) and advanced to Phase III in moderately-to-severely active ulcerative colitis. The Ametrine-2 induction study (NCT06588855, sponsor Hoffmann-La Roche) has a start date of December 11, 2024 and is recruiting; Phase II is ongoing in Crohn's disease and atopic dermatitis.
Promising but Pre-Revenue. Assessment of Roche Holding AG's $7.1B acquisition of Telavant Holdings and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Telavant Holdings (this deal) | 2023 | $7.1B | 73 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2023 deals · Roche Holding AG deals · Gastroenterology deals